Nivolumab is the first humanized anti-human programmed cell death protein 1 (PD-1) monoclonal antibody, and was approved for malignant melanoma (MM) in July 2014 in Japan [1]. This evidence concerns the gene PDCD1 and Miyoshi myopathy.